S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Has The Salesforce Turnaround Begun?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Has The Salesforce Turnaround Begun?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Has The Salesforce Turnaround Begun?
S&P 500   3,852.36
DOW   32,920.46
QQQ   300.92
15 Ways to Improve Your Credit
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Bed Bath & Beyond Is Circling the Drain
Pfizer Stock: What the Bulls and Bears are Getting Wrong
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
AMD Results Are No Reason To Buy Semiconductors... Yet
Allegro Microsystems Is A Well-Positioned Semiconductor Stock
Cash Holders STILL Aren't Taking Steps to Prepare (Ad)
Institutions are Buying up Procter & Gamble Shares, Should you?
Has The Salesforce Turnaround Begun?
NASDAQ:MBIO

Mustang Bio - MBIO Stock Forecast, Price & News

$0.66
-0.02 (-2.95%)
(As of 02/1/2023 12:00 AM ET)
Add
Compare
Today's Range
$0.64
▼
$0.68
50-Day Range
$0.32
▼
$0.72
52-Week Range
$0.32
▼
$1.20
Volume
286,746 shs
Average Volume
664,072 shs
Market Capitalization
$69.91 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Mustang Bio MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
620.7% Upside
$4.75 Price Target
Short Interest
Healthy
0.39% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.75) to ($0.80) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

354th out of 1,053 stocks

Pharmaceutical Preparations Industry

169th out of 519 stocks

See Top Rated MarketRank™ Stocks Here

MBIO stock logo

About Mustang Bio (NASDAQ:MBIO) Stock

Mustang Bio, Inc. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of a broad range of proprietary chimeric antigen receptor engineered T cell (CAR T) immunotherapies and gene therapies. It develops CAR T and CRISPR/Cas9-enhanced CAR T therapies across multiple cancers, as well as lentiviral gene therapy for XSCID. The firm's products include MB-101 IL13Ra2-specific CAR, MB-102 CD123 CAR, MB-103 HER2 CAR, MB-104 CS1 CAR, MB-105 PSCA CAR, MB-106 CD20 CAR, MB-107 XSCID Gene Therapy and Oncolytic Virus (C134). The company was founded on March 13, 2015 and is headquartered in Worcester, MA.

Receive MBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter.

MBIO Stock News Headlines

December 19, 2022 | finance.yahoo.com
Mustang Bio Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones
November 15, 2022 | finanznachrichten.de
Mustang Bio, Inc.: Mustang Bio Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
February 2, 2023 | Investor Place Media (Ad)
Cash Holders STILL Aren't Taking Steps to Prepare
Stocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.
October 6, 2022 | baystreet.ca
Mustang Bio Unchanged on Test Results
October 6, 2022 | finance.yahoo.com
Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of MB-106, a First-in-Class CD20-targeted, Autologous CAR T Cell Therapy to Treat B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia
September 23, 2022 | seekingalpha.com
Mustang Bio: This Horse May Gallop Still
September 8, 2022 | finance.yahoo.com
Mustang Bio to Participate in Upcoming September 2022 Investor Conferences
September 2, 2022 | finance.yahoo.com
Here's Why Mustang Bio, Inc. (MBIO) Looks Ripe for Bottom Fishing
February 2, 2023 | Investing Trends (Ad)
Solar Industry at Start of Long Bull Run?
The U.S. solar industry generated nearly $33 billion of private investment in the American economy in 2021 -- and analysts say it looks like the start of a long solar bull market. Leading the way is the just-signed Inflation Reduction Act of 2022. With its generous investment tax credits, the Act is expected to triple U.S. solar energy production over the next 5 years.
August 19, 2022 | seekingalpha.com
Mustang Bio (MBIO) Corporate Presentation - Slideshow
August 12, 2022 | benzinga.com
Recap: Mustang Bio Q2 Earnings
July 23, 2022 | nasdaq.com
Mustang Bio, Inc. (NASDAQ:MBIO) Shares Could Be 50% Below Their Intrinsic Value Estimate
July 17, 2022 | finance.yahoo.com
Mustang Bio, Inc. (NASDAQ:MBIO) insider upped their holding by 9.9% earlier this year
July 15, 2022 | uk.finance.yahoo.com
Mustang Bio, Inc. (MBIO)
June 22, 2022 | msn.com
Mustang Bio Shares Gain As FDA Grants Orphan Drug Status To Waldenstrom Drug
June 22, 2022 | seekingalpha.com
Mustang Bio CAR T cell therapy for rare blood cancer gets FDA orphan drug status
June 22, 2022 | marketwatch.com
Mustang Bio Gets Orphan Drug Designation for MB-106 Lymphoma Treatment
June 22, 2022 | finance.yahoo.com
Mustang Bio Announces Orphan Drug Designation Granted to MB-106, a CD20-targeted, Autologous CAR T Cell Therapy for the Treatment of Waldenstrom Macroglobulinemia
June 13, 2022 | seekingalpha.com
Mustang Bio updates interim data for blood cancer candidate
June 13, 2022 | finance.yahoo.com
Mustang Bio Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy
May 19, 2022 | seekingalpha.com
Mustang announces positive data from gene therapy trial to treat X-linked immunodeficiency
May 19, 2022 | finance.yahoo.com
Mustang Bio Posts Encouraging Interim Data From Gene Therapy Trial In Immunodeficiency
May 12, 2022 | finance.yahoo.com
Mustang Bio Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
May 12, 2022 | finance.yahoo.com
Mustang Bio Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress
May 4, 2022 | seekingalpha.com
Mustang Bio: The Market Is Missing This Opportunity
May 3, 2022 | finance.yahoo.com
Mustang Bio Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting
April 25, 2022 | finance.yahoo.com
Mustang Bio's CAR T Cell Therapy Shows Favorable Safety Profile, Response Rates In Blood Cancer Patients
See More Headlines
Receive MBIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Mustang Bio and its competitors with MarketBeat's FREE daily newsletter.

MBIO Company Calendar

Last Earnings
11/14/2022
Today
2/02/2023
Next Earnings (Estimated)
3/22/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:MBIO
CUSIP
N/A
CIK
1680048
Web
www.mustangbio.com
Phone
(781) 652-4500
Fax
N/A
Employees
102
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.75
High Stock Price Forecast
$7.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+620.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.79)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-66,370,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-87.56%
Return on Assets
-63.25%

Debt

Debt-to-Equity Ratio
0.42
Current Ratio
6.97
Quick Ratio
6.97

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.19 per share
Price / Book
0.55

Miscellaneous

Outstanding Shares
106,070,000
Free Float
103,946,000
Market Cap
$69.91 million
Optionable
Optionable
Beta
1.87

Key Executives

  • Manuel LitchmanManuel Litchman
    President, Chief Executive Officer & Director
  • Eliot M. Lurier
    Chief Financial Officer
  • Knut Niss
    Chief Technology Officer
  • Bruce Dezube
    Senior Vice President & Head-Clinical Development
  • Susan E. Ward
    Vice President-Clinical Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Institutional Transactions













MBIO Stock - Frequently Asked Questions

Should I buy or sell Mustang Bio stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Mustang Bio in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" MBIO shares.
View MBIO analyst ratings or view top-rated stocks.

What is Mustang Bio's stock price forecast for 2023?

3 analysts have issued twelve-month price targets for Mustang Bio's stock. Their MBIO share price forecasts range from $4.00 to $7.00. On average, they expect the company's stock price to reach $4.75 in the next year. This suggests a possible upside of 620.7% from the stock's current price.
View analysts price targets for MBIO or view top-rated stocks among Wall Street analysts.

How have MBIO shares performed in 2023?

Mustang Bio's stock was trading at $0.3949 at the beginning of the year. Since then, MBIO stock has increased by 66.9% and is now trading at $0.6591.
View the best growth stocks for 2023 here.

Are investors shorting Mustang Bio?

Mustang Bio saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 319,000 shares, a decrease of 23.6% from the December 31st total of 417,700 shares. Based on an average daily volume of 500,800 shares, the short-interest ratio is currently 0.6 days. Approximately 0.4% of the company's shares are short sold.
View Mustang Bio's Short Interest.

When is Mustang Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our MBIO earnings forecast.

How were Mustang Bio's earnings last quarter?

Mustang Bio, Inc. (NASDAQ:MBIO) posted its earnings results on Monday, November, 14th. The company reported ($0.18) earnings per share for the quarter, topping analysts' consensus estimates of ($0.20) by $0.02.

What other stocks do shareholders of Mustang Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Mustang Bio investors own include OPKO Health (OPK), Sorrento Therapeutics (SRNE), CymaBay Therapeutics (CBAY), TG Therapeutics (TGTX), VBI Vaccines (VBIV), Fortress Biotech (FBIO), Viking Therapeutics (VKTX), Selecta Biosciences (SELB), Aytu BioPharma (AYTU) and Kadmon (KDMN).

What is Mustang Bio's stock symbol?

Mustang Bio trades on the NASDAQ under the ticker symbol "MBIO."

Who are Mustang Bio's major shareholders?

Mustang Bio's stock is owned by many different retail and institutional investors. Top institutional shareholders include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Brian Achenbach, Lindsay A Md Rosenwald and Manuel Md Litchman.
View institutional ownership trends.

How do I buy shares of Mustang Bio?

Shares of MBIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Mustang Bio's stock price today?

One share of MBIO stock can currently be purchased for approximately $0.66.

How much money does Mustang Bio make?

Mustang Bio (NASDAQ:MBIO) has a market capitalization of $69.91 million. The company earns $-66,370,000.00 in net income (profit) each year or ($0.79) on an earnings per share basis.

How many employees does Mustang Bio have?

The company employs 102 workers across the globe.

How can I contact Mustang Bio?

Mustang Bio's mailing address is 377 PLANTATION STREET, WORCESTER MA, 01605. The official website for the company is www.mustangbio.com. The company can be reached via phone at (781) 652-4500 or via email at ir@mustangbio.com.

This page (NASDAQ:MBIO) was last updated on 2/2/2023 by MarketBeat.com Staff